Brief: Amneal Pharmaceuticals Says Crexont Commercial Launch Planned In September 2024
07/08/2024 23:25
Aug 7 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O :
* AMNEAL RECEIVES U.S. FDA APPROVAL FOR IPX203 FOR TREATMENT
OF
PARKINSON’S DISEASE TO BE LAUNCHED AS CREXONT® (CARBIDOPA AND
LEVODOPA) EXTENDED-RELEASE CAPSULES
* AMNEAL PHARMACEUTICALS INC - CREXONT COMMERCIAL LAUNCH
PLANNED
IN SEPTEMBER 2024
Source text for Eikon: ID:nBw1gQTlQa
Further company coverage: AMRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amneal Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-3M Company, Constellation Energy, Metropolitan Bank Holding
US FDA is working with manufacturers to boost estrogen patch supply amid access concerns (updated)
U.S. RESEARCH ROUNDUP- Intuit, MongoDB, Zscaler
U.S. STOCKS ON THE MOVE-Mastercard, Yum, Equinix
Amneal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary